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Prognostic Value of Immunohistochemical Biomarkers at 
Different Cut-off Values in Patients with Diffuse Large B-cell 
Lymphoma Treated with CHOP Chemotherapy
Many predictive models have been proposed for better stratification of diffuse large B-cell 
lymphoma (DLBCL). Hans’ algorithm has been widely used as standard to sub-classify 
DLBCL into germinal center B-cell (GCB) and non-GCB origins. However, there have been 
disagreements in the literature regarding its prognostic significance. Here, we 
retrospectively analyzed Hans’ algorithm and the individual immunohistochemical 
biomarkers at different cut-off values (5%, 30%, 50% or 75%) in 94 Korean patients with 
DLBCL treated with combination chemotherapy with cyclophosphamide, daunorubicin, 
vincristine, and prednisone. No significant differences were observed between the GCB (18 
patients, 19.1%) and non-GCB (76, 80.9%) groups. Among individual biomarkers, CD10 
negativity (cut point: 30%) and bcl-6 positivity (cut point: 5%) were independent good 
prognostic markers in progression-free survival (PFS), whereas bcl-6 (cut point: 5%) 
positivity was an independent good prognostic marker in overall survival irrelevant of 
international prognostic index. The present study showed the lack of predictability of Hans’ 
algorithm in DLBCL patients, and that CD10, Bcl-6 may have diverse prognostic 
significance at different cut-off values. Our results suggest that the proposed cut-off value 
may not be applied universally, and that the optimal cut-off value may need to be 
optimized for individual laboratory.
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INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) is the most common 
type of non-Hodgkin’s lymphoma (1, 2). Although DLBCL is con-
sidered as a specific category, the variable clinical outcomes, 
morphologic and genetic alterations reflect that these lympho-
mas are heterogeneous groups of tumor rather than single clin-
icopathologic entity (3). For prediction of the response of che-
motherapy and patient’s survival, international prognostic in-
dex (IPI) is widely used. The IPI includes 5 clinical parameters 
and its efficacy is relatively excellent (4). But it does not repre-
sent the biologic or genetic feature of the tumor.
  Recent subjects dealing with DLBCL heterogeneity have stud-
ied with genetic diversity and molecular alteration of this tumor. 
Particular attention has been focused on the relationship be-
tween B cell differentiation stage and the prognosis of DLBCL 
(3, 5). Gene expression profiling using cDNA microarray identi-
fied two distinct molecular subgroups with germinal center B-
cell-like (GCB) and non-germinal center B-cell-like (non-GCB). 
The GCB group has more favorable outcome than non-GCB 
group (6, 7). Although this analysis provided critical information 
about the molecular heterogeneity of DLBCL, it is not routinely 
used in clinical practice because of high cost and the necessity 
of fresh frozen samples for analysis. For that reason, the identi-
fication methods using immunohistochemistry of paraffin-em-
bedded tissue were developed by several groups (3, 5, 8). Most 
of these methods use CD 10 or bcl-6 as GCB markers and MUM1 
or CD138 as non-GCB markers. Among these studies, Hans’ 
method has been widely accepted as the standard in discrimi-
nating GCB group and non-GCB group of DLBCL patients (8). 
Because Hans’ algorithm is relatively simple and feasible, many 
laboratories adopted it as a standard method. However, few stud-
ies have demonstrated the validity of Hans’ discrimination meth-
od in predicting the prognosis of Asian DLBCL patients (9).
  It was known that single protein expression of each marker 
such as CD10, bcl-6, MUM-1, bcl-2 and CD5, also might provide 
clinical information in DLBCL (8, 10-13). However, studies of 
the protein expression have reported conflicting results. These 
results predominantly are due to the differences of the cut-off 
values and the lack of standardized approach for each marker. Oh S, et al.  •  Prognostic Value of IHC Markers for DLBCL
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Here we performed an analysis addressing the prognostic signif-
icance of Hans’ method in Korean DLBCL patients who treated 
with combination chemotherapy with cyclophosphamide, dau-
norubicin, vincristine, and prednisone (CHOP). We also inves-
tigate the clinical significance of individual biomarkers and com-
pared the results with different cut-off values.
MATERIALS AND METHODS
Patients
All patients who were consecutively diagnosed in Asan Medical 
Center between September 1999 and September 2004 were re-
trieved from the database of department of oncology. All of the 
patients received CHOP chemotherapy without rituximab. Inclu-
sion criteria for the study were a reference diagnosis of DLBCL 
(134 patients), and the availability of formalin-fixed and paraf-
fin-embedded material for tissue microarray construction (94 
patients). All cases were reviewed and were confirmed as DLBCL 
by two pathologists according to the WHO classification (2008). 
Patients with transformed lymphoma, AIDS associated tumor, 
primary mediastinal lymphoma, primary CNS lymphoma, stage 
I DLBCL, or received rituximab therapy were excluded. 
 
Tissue microarray, immunohistochemical staining of 
individual marker and sub-classification of DLBCL cases
For the tissue microarray (TMA), hematoxylin and eosin-stained 
sections from each paraffin-embedded, formalin-fixed block 
were used to define diagnostic areas. Two random, representa-
tive 0.6 mm cores were obtained from each case and inserted in 
a grid pattern into a recipient paraffin block using a tissue array-
er. Sections (5 µm) were cut from each TMA and stained with 
antibodies to CD20, CD10, bcl-6, MUM1, CD5, CD138, and bcl-
2 using the avidin-biotin method. The level of each immuno-
chemical marker was assessed by a modification of the method 
by Hans et al. (8) in which, a case was considered positive, when 
30% or more of the tumor cells were stained with the antibody. 
A 4-point system was devised based on the proportion of posi-
tive cell: 5%, 30%, 50%, and 75%. Each core was evaluated inde-
pendently by two pathologists, and in case of disagreement, third 
measurement by the joint review was adopted. The cases were 
sub-classified into GCB-derived DLBCL and non-GCB derived 
DLBCL according to the algorithm proposed by Hans et al. (8).
Statistical analysis
The survival analysis was performed according to the method 
of Kaplan and Meier. Overall survival (OS) was defined as the 
time from diagnosis to the date of death or last contact. Progres-
sion-free survival (PFS) was defined as the time from diagnosis 
to the date of progression, death or last contact. Patients were 
censored for OS at the time of the last contact if currently alive 
and for PFS if no progression or death had occurred at the time 
of their last visit. Survival data between defined subgroups were 
compared with the log-rank test. Multivariate analyses were 
carried out by a Cox regression model and were used to select 
variables with independent predictive significance. Statistical 
data processing was carried out with SPSS software. Probability 
values less than 0.05 were considered statistically significant.
Ethics statement
According to the declaration of Helsinski, the institutional re-
view board of Asan Medical Center approved this protocol (IRB 
No. 2009-0098; approval date: April 06 2009) and granted a waiv-
er of informed consent.
RESULTS
Patient characteristics
Clinical data were available for all 94 patients included in the 
study. The patients’ median age was 59 yr (range, 18-82) at diag-
nosis. The median follow up period was 60 months. Five-year 
progression free survival rate of the whole cases was 59% (95% 
CI, 54%-64%) and 5 yr overall survival rate was 64% (95% CI, 59%-
69%). The characteristics of these patients are listed in Table 1.
Sub-classification of DLBCL by Hans’ classification and 
Survival analysis 
Of the 94 cases of DLBCL, expression of CD10 was seen in 9 cases 
(9.5%), bcl-6 in 27 cases (28.7%), MUM1 in 70 cases (74.4%) at 
the 30% positivity of cut-off point. Using the algorithm of Hans 
et al., 18 cases (19.1%) were classified as GCB group and 76 cases 
(80.9%) were classified as non-GCB group. With a median fol-
low up of 5 yr, there was no significant survival difference be-
tween patients with GCB group and those with non-GCB group. 
The 5-yr PFS estimates ( ± SE) were 61% ± 11% for GCB group 
Table 1. Patient Characteristics (n = 94)
Characteristics No. (%) of patients
Age (yr)
   ≤ 60
   ≥ 60
 
51 (54)
43 (46)
Stage
   2
   3-4
 
47 (50)
47 (50)
Performance
   0-1
   2-3
 
88 (94)
6 (6)
LDH
   ≤ 1 × normal
   > 1 × normal
 
25 (27)
69 (73)
Extranodal involvement
   ≤ 1
   > 1
 
83 (88)
11 (12)
IPI score
   0-2
   3-5
 
70 (74)
24 (26)
LDH, lactate dehydrogenase; IPI, international prognostic index.Oh S, et al.  •  Prognostic Value of IHC Markers for DLBCL
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vs 58% ± 6% for non-GCB group (P = 0.79, Fig. 1A). For 5-yr OS, 
the estimates were 72% ± 11% for GCB group vs 62% ± 6% for 
non-GCB group (P = 0.40, Fig. 1B).
Immunohistochemical result of individual biomarker and 
its clinical relevance according to cut-off value of each 
marker
The percentage of positively-stained tumor cells and survival 
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Fig. 1. Kaplan-Meier curves of progression-free survival (PFS) (A) and overall survival (OS) (B) based on stratifying diffuse large B cell lymphomas (DLBCL) into germinal center 
B-cell (GCB) and non-germinal center B-cell (non-GCB) groups.
Table 2. Correlation of immunohistochemical marker and clinical outcomes of DLBCL patients
Markers No.
PFS  
(mean ± SD) 
(months)
P value
OS  
(mean ± SD) 
(months)
P value
CD10 5%
   (-)
   (+)
 
73
21
  
62.3 ± 5.7
47.6 ± 10.9
 
0.310
 
64.1 ± 5.7
61.9 ± 10.6
 
0.949
CD10 30%
   (-)
   (+)
 
85
9
 
62.9 ± 5.3
22.2 ± 13.9
 
0.013
 
65.7 ± 5.2
44.4 ± 16.6
 
0.210
CD10 50%
   (-)
   (+)
 
87
7
 
61.4 ± 5.3
28.6 ± 17.1
 
0.117
 
65.3 ± 5.1
42.9 ± 18.7
 
0.264
CD10 75%
   (-)
   (+)
 
89
5
 
60.0 ± 5.3
40.0 ± 21.9
 
0.676
 
63.8 ± 5.1
60.0 ± 21.9
 
0.971
bcl-6 5%
   (-)
   (+)
 
54
40
 
47.2 ± 6.9
74.2 ± 7.1
 
0.004
 
49.9 ± 6.8
82.2 ± 6.1
 
0.001
bcl-6 30%
   (-)
   (+)
 
67
27
 
51.5 ± 6.2
76.7 ± 8.4
 
0.018
 
58.2 ± 6.0
77.2 ± 8.2
 
0.052
bcl-6 50%
   (-)
   (+)
 
77
17
 
55.2 ± 5.7
74.5 ± 11.2
 
0.101
 
61.0 ± 5.6
75.5 ± 10.7
 
0.173
bcl-6 75%
   (-)
   (+)
 
83
11
 
55.9 ± 5.5
80.8 ± 12.2
 
0.116
 
61.3 ± 5.4
81.8 ± 11.6
 
0.190
MUM-1 5%
   (-)
   (+)
 
12
82
 
66.7 ± 13.6
57.7 ± 5.5
 
0.615
 
75.0 ± 12.5%
61.9 ± 5.4%
 
0.506
MUM-1 30%
   (-)
   (+)
 
24
70
 
70.8 ± 9.3
54.6 ± 6.0
 
0.197
 
79.2 ± 8.3
58.3 ± 5.9
 
0.107
MUM-1 50%
   (-)
   (+)
 
45
49
 
62.0 ± 7.3
55.9 ± 7.2
 
0.496
 
68.7 ± 7.0
59.0 ± 7.0
 
0.297
DLBCL, diffuse large B cell lymphoma; PFS, progression free survival; OS, overall survival.
 
Markers No.
PFS  
(mean ± SD) 
(months)
P value
OS  
(mean ± SD) 
(months)
P value
MUM-1 75%
   (-)
   (+)
 
53
41
 
58.3 ± 6.8
59.6 ± 7.8
 
0.938
 
64.0 ± 6.6
63.2 ± 7.6
 
0.895
bcl-2 5%
   (-)
   (+)
 
31
62
 
62.9 ± 8.9
56.2 ± 6.3
 
0.453
 
67.6 ± 8.4
61.2 ± 6.2
 
0.523
bcl-2 30%
   (-)
   (+)
 
53
40
 
59.3 ± 7.9
57.3 ± 7.9
 
0.785
 
65.8 ± 6.5
60.0 ± 7.7
 
0.552
bcl-2 50%
   (-)
   (+)
 
53
40
 
59.3 ± 6.9
57.3 ± 7.9
 
0.785
 
65.8 ± 6.5
    60 ± 7.7
 
0.552
bcl-2 75%
   (-)
   (+)
 
57
36
 
62.2 ± 6.5
52.5 ± 8.4
 
0.318 68.2 ± 6.2
55.6 ± 8.3
0.209
CD5 5% 
   (-)
   (+)
 
57
34
 
67.4 ± 6.3
41.2 ± 8.4
 
0.009
 
70.0 ± 6.1
49.8 ± 8.6
 
0.06
CD5 30%
   (-)
   (+)
 
67
24
 
63.3 ± 6.0
41.7 ± 10.1
 
0.053
 
65.5 ± 5.8
53.8 ± 10.2
 
0.319
CD5 50%
   (-)
   (+)
 
76
15
 
59.6 ± 5.7
46.7 ± 12.9
 
0.425
 
63.0 ± 5.6
59.3 ± 12.9
 
0.975
CD5 75%
   (-)
   (+)
82
9
58.9 ± 5.5
44.4 ± 16.6
 
0.458
 
62.0 ± 5.4
66.7 ± 15.9
 
0.713
IPI score
   0-2
   3-5
 
70
24
 
69.4 ± 5.6
28.6 ± 9.4
 
< 0.001
 
74.2 ± 5.2
32.8 ± 9.7
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analysis of each biomarker at the different cut off value point 
are recorded in Table 2. There was no statistical difference of IPI 
scores (0-2 vs 3-5) between positive and negative group of all 
biomarkers except bcl-2 by the cut-off point of 75% (P = 0.043). 
The survival analysis of each biomarker showed variable results 
with different cut-off point for each marker. Although bcl-6 pos-
itive group had longer PFS than negative group, PFS difference 
was narrowed down from the cut-off point of 5% (P = 0.004) to 
the cut-off point of 75% (P = 0.116). 
In univariate analysis, CD10 negative DLBCL had longer PFS 
than CD10-positive group at the cut-off point of 30% (P = 0.013; 
Fig. 2A). CD 10 positivity did not have clinical meaning at any of 
the other cut-off points. As we mentioned earlier, bcl-6 positive 
group had significant longer PFS. The bcl-6 positivity had a clini-
cal value at both cut off point of 5% (P = 0.004; Fig. 2B) and 30% 
(P = 0.018) in PFS analysis. CD5 negative group had longer PFS 
than CD5 positive group at the cut-off point of 5% (P = 0.009). 
The IPI had a high value for predicting PFS (P < 0.001). The bcl-6 
positive group had longer OS than negative group at the cut-off 
point of 5% (P = 0.001; Fig. 3). The IPI also had a high value for 
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
p
r
o
g
r
e
s
s
i
o
n
 
f
r
e
e
 
s
u
r
v
i
v
a
l
 
(
%
)
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
p
r
o
g
r
e
s
s
i
o
n
 
f
r
e
e
 
s
u
r
v
i
v
a
l
 
(
%
)
Duration (months) Duration (months)
0  20  40  60  80  100  120 0  20  40  60  80  100  120
100
80
60
40
20
0
100
80
60
40
20
0
A B
CD10 negative
CD10 positive
bcl-6 positive
bcl-6 negative
Fig. 2. Kaplan-Meier curves of progression free survival (PFS) according to CD10 (cut-off 30%) (A) and bcl-6 (cut-off 5%) (B).
Table 3. Prognostic factors affecting PFS and OS, Multivariate analysis including IPI 
scores
Clinical outcome Hazard ratio 95% CI P value
PFS
   CD10 ≥ 30% 
   bcl-6 ≥ 5%
   IPI 0-2 vs 3-5
 
4.816
0.340
3.297
 
  2.02 to 11.49
0.16 to 0.72
1.67 to 6.50
 
< 0.001
0.005
0.001
OS
   bcl-6 ≥ 5%
   IPI 0-2 vs 3-5
0.281
2.966
0.12 to 0.65
1.49 to 5.87
0.003
0.002
CI, confidence interval; PFS, progression free survival; OS, overall survival; IPI, inter-
national prognostic index.
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Fig. 3. Kaplan-Meier curves of overall survival (OS) according to bcl-6 (cut-off 5%).
predicting OS (P < 0.001). The expression of MUM1 and bcl-2 did 
not correlate with the survival of DLBCL patients in our study.
  The results of Cox multivariate analyses showed that CD 10 
expression at the cut-off point of 30%, bcl-6 expression at the 
cut-off point of 5% and IPI score were independent prognostic 
factors of PFS. For OS, bcl-6 expression at the cut-off point of 5% 
and IPI score were independent prognostic factors of OS in mul-
tivariate analysis (Table 3).
DISCUSSION
Many predictive models have been proposed for better stratifi-
cation of DLBCL using immunohistochemical stains for germi-
nal center B-cell marker or activated B-cell marker (3, 8, 10). The 
Nebraska Lymphoma Study Group proposed a classification  
algorithm (Hans’ method) using immunohistochemical stain 
with CD10, bcl-6 and MUM-1 (8). It is generally accepted that 
classification of DLBCL by Hans’ algorithm gives relevant prog-
nostic information for DLBCL patients treated with CHOP che-
motherapy, although it does not reliably predict the survival of 
DLBCL patients who relapsed or were refractory to initial che-
motherapy (14, 15). Recent studies have reported the usefulness 
of Hans’ algorithm even in the rituximab-based chemotherapy 
era (16, 17). However, there is a disagreement on the prognostic Oh S, et al.  •  Prognostic Value of IHC Markers for DLBCL
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value of Han’s classification method in DLBCL patients in the 
literature (18-20). No correlation was reported between Hans’ 
classification and the survival in the DLBCL patients treated by 
CHOP or CHOP-like chemotherapy, or CHOP with rituximab 
in the previous retrospective or prospective studies (18-20). The 
lack of clinical usefulness of the Hans’ classification method in 
predicting the survival of Korean patients with DLBCL treated 
with CHOP chemotherapy in the present study agrees with the 
previous reports, and illustrates the limitation of the currently 
available immunohistochemical discrimination of the GCB ver-
sus non-GCB groups (18-20). The Hans’ method has 70%-80% 
concordance with the gene expression profiling (GEP) classifica-
tion, while, the remaining 20%-30% is discrepant (8, 18). A new 
immunostain algorithm recently proposed by Nebraska group 
uses GCET1, CD10, bcl-6, MUM-1 and FOXP1 (21). Although 
its reported concordance rate with GEP classification is 93%, its 
clinical usefulness should be tested in large scale studies in dif-
ferent populations.
  Whereas each biomarker had prognostic significance at the 
uniform cut off value of 30% in the Hans’ reports and other stud-
ies, each biomarker showed variable results at the cut off value 
of 30% in the present study (8). As a marker of germinal center, 
CD10 is generally associated with better prognosis. Interestingly, 
CD 10 expression was an independent negative prognostic fac-
tor of PFS in the present study. Although the small sample size 
warrants caution in the interpretation, the findings calls for fur-
ther study in the Korean population on a larger scale to rule out 
ethnic or regional differences. The low positivity of CD10 stain 
and high positivity of MUM-1, and the lower proportion of GCB 
group compared to Western population in our study are in agree-
ment with the previous reports from Japan and China (22, 23). 
  The BCL6 proto-oncogene, a gene essential for the germinal 
center formation, is the most commonly translocated gene in 
DLBCL (24, 25). The expression of bcl-6 protein had a predictive 
power in both PFS and OS irrelevant of IPI, in agreement with 
the previous reports (8, 26). Expression of MUM-1 signifies the 
step of B-cell maturation toward plasma cell, and serves as a 
marker of activated B-cell (10, 27). It was reported that MUM1 
expression was related with worse survival of DLBCL patients 
(8, 10). Unlike the previous reports of the deleterious effect of 
MUM1 expression on survival, MUM1 expression had little im-
pact on survival of DLBCL patients in this study. CD5 is an anti-
gen expressed by most T cells and a subset of B cells, and can be 
infrequently expressed by DLBLCL (28). It is known that CD5 
positive DLBLC tumors are observed in elderly women with 
high IPI score and poor survival (13). In the univariate survival 
analysis of our study, CD5 expression had a prognostic signifi-
cance for both PFS and OS. But this prognostic significance be-
came negligible in multivariate analysis.
   We showed that prognostic significance of each biomarker 
varied with different cut-off value. Inter-laboratory technical 
variations (such as different primary antibodies, different fixa-
tion method, various antigen retrieval and signal amplification 
technique) and inter-observer variations exist (29). In a typical 
referral center where consultation cases make the significant 
portion of the cases, the laboratory or the pathologist have no 
control over many pre-analytic variables including fixation meth-
od or the duration of fixation. To overcome these technical vari-
ations, Lunenburg lymphoma biomarker consortium recom-
mended the centralized consensus review and validated assess-
ment of biomarkers in each laboratory (30). On the other hand, 
there may be variations in the significance of these markers among 
different populations, as seen in this study. We propose that set-
ting up of an optimal cut-off value of each biomarker in the in-
dividual laboratory is a viable option.
  In conclusion, Hans’ classification method subdividing DLBCL 
to GCB group and non-GCB group had no clinical significance 
in our study. CD10 negative expression and bcl-6 positive ex-
pression group had favorable outcomes in DLBCL patients who 
treated with CHOP chemotherapy. Because prognostic signifi-
cance of each biomarker is varied with different cut-off value, 
the cut-off level of biomarker is needed to be determined with 
individual institutions’ clinical results.
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Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in 
Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy
Sukjoong Oh, Dong Hoe Koo, Cheolwon Suh, Shin Kim, Bong Hee Park, Joon Kang and Jooryung Huh
Hans’ algorithm has been widely used to sub-classify diffuse large B-cell lymphoma (DLBCL). However, there is a disagreement in 
the literature regarding its prognostic significance. Here, we retrospectively analyzed Hans’ algorithm and the individual 
immunohistochemical biomarkers at different cut-off values in 94 DLBCL patients. Although no significant differences were 
observed between the subgroups, CD10 negativity (cut point: 30%) and bcl-6 positivity (cut point: 5%) were independent good 
prognostic markers. It is requested to obtain the optimized cut-off values of Han’s algorithm for individual laboratory.